The researchers have devised an SRM workflow using extensive fractionation and multiple dimensions of separation to measure proteins at picograms per mL levels.
Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
The test, which measures the kinetics of amyloid beta isoforms in blood, could enable more efficient screening of patients for Alzheimer's drug trials.
